John Temperato - Net Worth and Insider Trading
John Temperato Net Worth
The estimated net worth of John Temperato is at least $7 dollars as of 2024-11-29. John Temperato is the CEO of 9 Meters Biopharma Inc and owns about 71,376 shares of 9 Meters Biopharma Inc (NMTRQ) stock worth over $7. Details can be seen in John Temperato's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that John Temperato has not made any transactions after 2022-07-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of John Temperato
John Temperato Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, John Temperato owns 2 companies in total, including 9 Meters Biopharma Inc (NMTRQ) , and Melinta Therapeutics Inc (MLNTQ) .
Click here to see the complete history of John Temperato’s form 4 insider trades.
Insider Ownership Summary of John Temperato
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
NMTRQ | 9 Meters Biopharma Inc | 2022-07-06 | director & Chief Executive Officer |
MLNTQ | Melinta Therapeutics Inc | 2017-11-03 | Chief Commercial Officer |
John Temperato Latest Holdings Summary
John Temperato currently owns a total of 1 stock. John Temperato owns 71,376 shares of 9 Meters Biopharma Inc (NMTRQ) as of July 6, 2022, with a value of $7.
Latest Holdings of John Temperato
Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
---|---|---|---|---|---|
NMTRQ | 9 Meters Biopharma Inc | 2022-07-06 | 71,376 | 0.00 | 7 |
Holding Weightings of John Temperato
John Temperato Form 4 Trading Tracker
According to the SEC Form 4 filings, John Temperato has made a total of 10 transactions in 9 Meters Biopharma Inc (NMTRQ) over the past 5 years, including 10 buys and 0 sells. The most-recent trade in 9 Meters Biopharma Inc is the acquisition of 6,250 shares on July 6, 2022, which cost John Temperato around $28,750.
Insider Trading History of John Temperato
- 1
John Temperato Trading Performance
GuruFocus tracks the stock performance after each of John Temperato's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by John Temperato is 20.86%. GuruFocus also compares John Temperato's trading performance to market benchmark return within the same time period. The performance of stocks bought by John Temperato within 3 months outperforms 5 times out of 10 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how John Temperato's insider trading performs compared to the benchmark.
Performance of John Temperato
John Temperato Ownership Network
John Temperato Owned Company Details
What does 9 Meters Biopharma Inc do?
Who are the key executives at 9 Meters Biopharma Inc?
John Temperato is the director & Chief Executive Officer of 9 Meters Biopharma Inc. Other key executives at 9 Meters Biopharma Inc include Chief Financial Officer Bethany Sensenig , Chief Financial Officer Edward J Sitar , and 10 percent owner Orbimed Israel Biofund Gp Limited Partnership .
9 Meters Biopharma Inc (NMTRQ) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of 9 Meters Biopharma Inc (NMTRQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of 9 Meters Biopharma Inc (NMTRQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
9 Meters Biopharma Inc (NMTRQ)'s detailed insider trading history can be found in Insider Trading Tracker table.
9 Meters Biopharma Inc Insider Transactions
John Temperato Mailing Address
Above is the net worth, insider trading, and ownership report for John Temperato. You might contact John Temperato via mailing address: C/o Melinta Therapeutics,inc., 300 George Street, Suite 301, New Haven Ct 06511.